Anúncio
Anúncio
MRNA
Moderna, Inc. Common Stock
35.90
USDPatrocinado
+0.24
+0.68%
07 de jan., 13:22 UTC -5
Abrir
Relatórios de Lucros MRNA
Rácio de surpresa positiva
MRNA separação 19 de 28 últimas estimativas.
68%
Próximo Relatório
Data do Próximo Relatório
12 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$659.58M
/-$2.77
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-35.08%
/+443.14%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-31.72%
/-4.81%
Moderna, Inc. Common Stock earnings per share and revenue
On 06 de nov. de 2025, MRNA reported earnings of -0.51 USD per share (EPS) for Q3 25, beating the estimate of -2.14 USD, resulting in a 76.27% surprise. Revenue reached 1.02 bilhão, compared to an expected 904.27 milhão, with a 12.36% difference. The market reacted with a +3.27% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analistas forecast an EPS of -2.77 USD, with revenue projected to reach 659.58 milhão USD, implying an aumentar of 443.14% EPS, and diminuir of -35.08% in Revenue from the last quarter.
FAQ
What were Moderna, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Moderna, Inc. Common Stock reported EPS of -$0.51, beating estimates by 76.27%, and revenue of $1.02B, 12.36% above expectations.
How did the market react to Moderna, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 3.27%, changed from $23.56 before the earnings release to $24.33 the day after.
When is Moderna, Inc. Common Stock expected to report next?
The next earning report is scheduled for 12 de fev. de 2026.
What are the forecasts for Moderna, Inc. Common Stock's next earnings report?
Based on 18
analistas, Moderna, Inc. Common Stock is expected to report EPS of -$2.77 and revenue of $659.58M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio